Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $76 ...
Mirdametinib has the potential to be the first approved therapy for the treatment of adult patients and a best-in-class therapy...
The NDA was granted Priority Review and has been given a Prescription Drug User Fee Act (PDUFA) action date of February 28, 2025.
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate...
In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application (MAA) with the European Medici...
- SEC Filing
- SEC Filing
- SEC Filing
